Medicine

GnRH Antagonist Protects Ovarian Function During Chemotherapy

August 2, 2007
Source: 23rd Annual Conference of the European Society of Human Reproduction and Embryology, 1-4 July 2007, Lyon, France

&ot&uot


Kate Stern

REFERENCE: O-144
KATE STERN, Royal Women’s Hospital, Melbourne
A potential new way of preserving ovarian function during chemotherapy for cancer could be treatment with an antagonist of gonadotropin-releasing hormone: GnRH. A pilot study from Melbourne looked at 18 young women with cancer or auto immune disease due to receive cyclophosphamide therapy. Sarah Maxwell spoke with Kate Stern and heard more about the study.

Similar Interviews

  • Ovarian Stimulation Does Not Affect Fetal Birth Weight – reporting from 23rd Annual Conference of the European Society of Human Reproduction and Embryology, 1-4 July 2007, Lyon, France

    • &ot

  • Fewer, Not More, Live Births After Preimplantation Genetic Embryo Screening – reporting from European Society of Human Reproduction and Embryology 23rd Annual Meeting, Lyon, July 1-4, 2007

    • Sjoerd Repping REFERENCE: ABSTRACT Oral 278, also: N Engl J Med 2007;357:9-17 SJOERD REPPING, University of Amsterdam Genetic screening

  • Cortical Grafting Or Intact Ovary Transplantation for Preserving Fertility?

    1. [...] study from Melbourne looked at 18 young women with cancer or auto … article continues at admin brought to you by cancer.medtrials.info and [...]

      Posted by   Audio Journal of Medicine: GnRH Antagonist Protects Ovarian … by cancer.MEDtrials.info | August 2, 2007, 8:58 pm

    Post a comment